Baird raises price targets on Biogen and Icon shares
Dow Jones Newswires reports Baird lifted its Biogen target to $290 from $250 and Icon's to $249 from $210, keeping Icon at Outperform.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Dow Jones Newswires reports that Baird analysts raised their price target on Biogen shares to $290 from $250. Separately, Baird increased its Icon target to $249 from $210 and maintained its Outperform rating. The information is based on a ratings roundup compiled by Benzinga.
why it matters
Price target revisions like these are routine and reflect individual analysts' views rather than changes in the companies' underlying fundamentals. For the broader market they usually matter only as a signal about sentiment toward specific stocks.
tags
instruments
sources
- Biogen Price Target Raised to $290.00/Share From $250.00 by Baird — Dow Jones Newswires, 29 October 2026 at 11:21 UTC
- Icon Price Target Raised to $249.00/Share From $210.00 by Baird — Dow Jones Newswires, 29 October 2026 at 11:37 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗